Diemond-Hernández JBB, Vázquez-Rosales JG, Beirana-Palencia L, Miranda-Novales MG

Language: Spanish
References: 14
Page: 155-158
PDF size: 52.20 Kb.

ABSTRACT

Bacterial endocarditis is a rare entity in pediatrics, generally associated to congenital cardiac defects. Even though the etiology is confirmed in most of the cases, some patients received empirical therapy for common isolated microorganisms. Linezolid is an oxazolidinone, with activity against Gram-positive cocci resistant to penicillin, methicillin vancomycin. Objective. To describe the results of the treatment with linezolid in a patient with bacterial endocarditis and bibliographic review. Description of the case. Female, 8 years of age, with congenital heart disease (double pulmonary lesion and patent ductus arterious), and diagnosis of bacterial endocarditis, confirmed by echocardiography four vegetations of variable sizes, from 12 to 15 mm, pediculated, in the pulmonary valve and internal right wall of pulmonary artery). She began treatment with penicillin G, plus amikacin. After an inital period of clinical response, fever reappeared at 7° day, and at two weeks, the size of the vegetations was bigger and new ones were noted. By consense, penicillin G was substituted with linezolid, with clinical improvement at two weeks, and cure at six weeks. Conclusions. Linezolid could be an alternative to conventional treatment for bacterial endocarditis in children without clinical improvement. Controlled randomized clinical trials are needed to prove its efficacy in this clinical entity.

REFERENCES

1. Durack DT. Approach to diagnosis of infective endocarditis. Clin Microbiol Infect 1998;4(Suppl 3):S3-S9.

2. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999;33(7):2023-9.

3. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96(3):200-9.

4. Guiscafre GH, Fierro H, Baca C, Muñoz O. Endocarditis bacteriana en la edad pediátrica. Revisión de 27 casos. Gac Med Méx 1980;116:371.

5. Ferrieri P, Gewitz MH, Gerber MA, Newburger JW, Dajani AS et al. Unique feature of infective endocarditis in childhood. Pediatrics 2002;109:931-43.

6. Saiman L, Prince A, Gersony WM. Pediatric infective endocarditis in the modern era. J Pediatr 1993;122:847-53.

7. Kaplan SL. Use of Linezolid in Children. Pediatr Infect Dis J 2002;21(1):870-2.

8. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32(9):1373-5.

9. Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of Vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001;45(2): 621-3.

10. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45(8):2304-8.

11. Jacqueline C, Batard E, Perez L, Boutoille D, Hamel A et.al. In vivo efficacy of continuous infusion versus intermittent dosing of Linezolid compared to Vancomycin in a methicillinresistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob Agents Chemother 2002;46(12):3706-11.

12. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002;35(8):1018-20.

13. Viale P, Scolari C, Colombini P, Cristini F, Cadeo B, Pagani L. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: a case report. J Chemother 2002;14(5):526-9.

14. Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with Linezolid. Clin Infect Dis 2002;35(1):902-3.